Extending the effective lifetime of stents

Implanted stents can reopen obstructed arteries, but regrowth of cells into the vessel wall can entail restenosis. Research at LMU now shows that an antimicrobial peptide inhibits restenosis and promotes vascular healing. Thus, coating stents with this peptide could increase their clinical efficacy.

Atherosclerosis is a major contributor to worldwide mortality and is characterized by narrowing of the arteries due to a thickening of the . This restricts to the tissues and can lead to heart attack or stroke. In many cases, implantation of a stent can successfully be used for of the obstructed or stenosed arteries to improve blood flow. However, when a regrowth of cells occurs in the inner vessel wall (the intima) or healing of the endothelial cell lining in the vessel lumen is incomplete, the result can be a restenosis, i.e. recurrent arterial obstruction and restriction of blood flow.

A research team led by LMU's Professor Christian Weber has now shown that a specific cell type called neutrophils, and molecules that they secrete, inhibit this life-threatening complication – which is observed in up to one-third of all stent implantations.

One of the products secreted by neutrophils, a short peptide named cathelicidin, promotes the healing of damaged blood vessels and patency of the stents by improving endothelial cell recovery, and prevents the formation of so-called neointima, which consists of cells of the inner vessel wall that contribute to restenosis at the site of stent implantation. Indeed, experiments in mice demonstrated that the incidence of restenosis was significantly reduced when miniaturized stents were coated with the peptide.

"Most modern stents release compounds aiming to block cell growth and inhibit inflammation – nevertheless restenoses and other serious complications, such as thromboses, can still occur ," says Weber, Director of the Institute for Cardiovascular Prevention at Munich University Medical Center. "We hope that cathelicidin-coated stents have the expected effect in human subjects. Moreover, we plan to use our model systems to test the effects of other products secreted by , as well as other peptides with similar functions to cathelicidin."

More information: Science Translational Medicine, online, 5. October 2011.

Provided by Ludwig-Maximilians-Universitat Munchen

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Promising 3-year data: Saving limbs with drug-eluting stents

Mar 10, 2009

Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), ...

Best use of drug-eluting stents

Sep 02, 2008

Compared with bare metal stents, drug-eluting stents substantially reduce the risk of angiographic and clinical recurrence but do not affect mortality or the short term or long term risk of myocardial infarction. The use ...

Boston Scientific admits stent risks

Sep 07, 2006

The U.S.-based Boston Scientific Corp. has admitted there is an increased risk of blood clots caused by use of its drug-coated cardiac stent.

Recommended for you

New molecule sneaks medicines across the blood/brain barrier

55 minutes ago

Delivering life-saving drugs across the blood-brain barrier (BBB) might become a little easier thanks to a new report published in the November 2014 issue of The FASEB Journal. In the report, scientists describe an antibo ...

Clock gene dysregulation may explain overactive bladder

55 minutes ago

If you think sleep problems and bladder problems are a fact of life in old age, you may be right. A new report appearing in the November 2014 issue of The FASEB Journal, shows that our sleep-wake cycles are genetically connec ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.